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ABSTRACT
TypeIIDNAtopoisomeraseshavebeenclassifiedinto
two families, Topo IIA and Topo IIB, based on struc-
tural and mechanistic dissimilarities. Topo IIA is the
targetofmanyimportantantibioticsandantitumoural
drugs, most of them being inactive on Topo IIB. The
effects and mode of action of Topo IIA inhibitors
in vitro and in vivo have been extensively studied
for the last twenty-five years. In contrast, studies of
Topo IIB inhibitors were lacking. To document this
field, we have studied two Hsp90 inhibitors (radicicol
and geldanamycin), known to interact with the ATP-
bindingsiteofHsp90(theBergeratfold),whichisalso
present in Topo IIB. Here, we report that radicicol
inhibits the decatenation and relaxation activities of
Sulfolobus shibatae DNA topoisomerase VI (a Topo
IIB) while geldanamycin does not. In addition, radi-
cicol has no effect on the Topo IIA Escherichia coli
DNA gyrase. In agreement with their different effects
on DNA topoisomerase VI, we found that radicicol
can theoretically fit in the ATP-binding pocket of the
DNA topoisomerase VI ‘Bergerat fold’, whereas geld-
anamycin cannot. Radicicol inhibited growths of
Sulfolobus acidocaldarius (a crenarchaeon) and of
Haloferax volcanii (a euryarchaeon) at the same
doses that inhibited DNA topoisomerase VI in vitro.
In contrast, the bacteria E.coli was resistant to this
drug. Radicicol thus appears to be a very promising
compound to study the mechanism of Topo IIB
invitro,aswellasthebiologicalrolesoftheseenzymes
in vivo.
INTRODUCTION
Type II DNA topoisomerases (Topo II) are ubiquitous
enzymes that catalyse the ATP-dependent crossing of two
DNA duplexes through each other via transient double-
strand breaks (DSBs) (1,2). They are implicated in major
biological processes such as replication, recombination and
transcription. In particular, the decatenation activity of
Topo II is essential in all organisms to separate daughter
chromosomes at the end of one replication round. In bacteria
and archaea, Topo II are also the only enzymes that can
remove positive superturns induced by the movement of
RNA and DNA polymerases, since prokaryotic type I DNA
topoisomerases (Topo I) can only relax negative superturns.
Topo II has been classiﬁed into two evolutionarily distinct
protein families: Topo IIA and Topo IIB [(3), for review see
(4)]. The Topo IIA family is represented by the ‘classical’
eukaryotic Topo II, the bacterial DNA gyrase (also present
in some archaea), the DNA topoisomerase IV and several viral
DNA topoisomerases. The prototype of the Topo IIB family is
the archaeal DNA topoisomerase VI. Most archaea only con-
tain DNA topoisomerase VI, but a few of them also contain a
bacterial-like DNA gyrase (4). Furthermore recently, putative
DNA topoisomerase VI turned out to be also present in plants
beside the classical Topo IIA (5,6).
The two families of Topo II resemble each other in terms of
enzymatic activities and organization of their functional
domains. In both cases, an ATP-binding module, which trig-
gers conformational change in the protein, is associated with a
DNA nicking-closing module that controls the formation of
transient DSBs. Both Topo IIA and Topo IIB use a tyrosine to
cleave DNA, leading to the formation of a transient 50
phospho-tyrosine linkage which is used to store the energy
required for the subsequent ligation step. The ATP-binding
modules of Topo IIA and IIB are homologues, since they
exhibit both sequence similarities in their N-terminal regions
and a common three-dimensional structure known as the
‘Bergerat fold’ (2,7–9). In contrast, the nicking-closing mod-
ules of Topo IIA and Topo IIB are non-homologous, being
structurally dissimilar (10). Furthermore, the production of
DSB by Topo IIA is ATP independent and generates single-
stranded extension of 4 bp, whereas DSB formation by Topo
IIB is ATP-dependent and generates single-stranded extension
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doi:10.1093/nar/gki526of 2 bp (11). These data indicate that the type II DNA
topoisomerase activity has been invented twice in the course
of evolution by the independent recruitment of two different
nicking-closing modules to work with the same type of ATP-
binding module (4).
Topo IIA have been studied extensively, in particular
because they are important cellular targets for anti-cancer
agents and antibiotics [for recent reviews, see (12–14)].
Two main classes of drugs have been described that affect
different steps of the catalytic cycle: drugs of the ﬁrst class
stabilizes the covalent complexes formed between the
DNA and the Topo II linked to the DSB (known as the
cleavable complex) converting the enzyme into a physiolo-
gical poison and drugs of the second class, sometimes referred
as ‘catalytic inhibitors’, which are those acting at any other
steps of the cycle. Most antitumoural drugs (such as epido-
phylotoxins, ellipticins and anthracyclins) as well as antibi-
otics of the quinolone and ﬂuoroquinolone families (like
nalidixic acid or perﬂoxacin) belong to the ﬁrst class, whereas
a few antitumoural drugs and antibiotics of the coumarin
family belong to the second one. These inhibitors might either
interfere with the binding between DNA and the enzyme (i.e.
the anthracyclin aclarubicin), stabilize the non-covalent com-
plex between the DNA and the Topo II (i.e. merbarone, ICRF-
193 and its bisdioxopiperazine derivatives) or else inhibit
ATP binding (coumarins). In parallel with structural studies,
the variety of inhibitors available to study Topo IIA has been
essential to describe in detail the catalytic cycle of these
fascinating enzymes and to analyse their numerous cellular
functions.
In contrast to the wealth of studies performed with Topo
IIA inhibitors, very little information is available on inhib-
itors of Topo IIB. We have previously shown that the
unknotting activity of Sulfolobus shibatae DNA topo-
isomerase VI was inhibited by several antitumoural drugs
known to be DNA intercalants (ellipticin, m-AMSA, donoru-
bicin and doxorubicin) and by VP16, a DNA topoisomerase
II poison which inhibits the resealing of DNA breaks created
by the enzyme, at concentrations similar to those used to
inhibit eukaryotic Topo IIA (15). In contrast, S.shibatae
DNA topoisomerase VI was not sensitive to compounds which
have no DNA-binding properties, such the bacterial Topo
IIA inhibitors (novobiocin, coumermycin and nalidixic acid).
In order to look for new drugs active against Topo IIB, we
have tested the effect of two inhibitors of the heat-shock
protein Hsp90, radicicol and geldanamycin, on S.shibatae
DNA topoisomeraseVI.These twodrugsare knowntointeract
with the Bergerat fold of Hsp90 (16), suggesting that they
could also interact with the Bergerat fold of DNA topoiso-
merase VI. We also tested the effect of radicicol and geldana-
mycin on the growth of the archaea, Haloferax volcanii and
Sulfolobus acidocaldarius, which are representatives of the
two known archaeal phyla, euryarchaeota and crenarchaeota,
respectively. Finally, we performed an in silico analysis of the
complexes between radicicol, geldanamycin and the archaeal
DNA topoisomerase VI. Our results show that radicicol, but
not geldanamycin, inhibits the archaeal DNA topoisomerase
VI in vitro and the archaeal growth in vivo. Radicicol thus
appears to be a very promising compound to study the mech-
anism of Topo IIB in vitro, as well as the biological roles of
these enzymes in vivo.
MATERIALS AND METHODS
Drugs were purchased from Sigma Aldrich. Concentrated
stock solutions (100 mM) were prepared in dimethyl sulfoxide
(DMSO), except novobiocin (H20). Stock solutions were ali-
quoted and stored at  20 C in the dark. For in vitro tests, the
drugs were diluted in DMSO. S.shibatae DNA topoisomerase
VI was puriﬁed as a heterotetramer after co-expression and
overproduction of the two subunits, Top6A and Top6B in
Escherichia coli, as previously described (11). E.coli DNA
gyrase was purchased from TopoGEN. The enzymes were
tested using as substrates kDNA for decatenation assay,
negatively supercoiled pBR322 plasmids for relaxation
assay, and relaxed pBR322 plasmids for supercoiling assay.
kDNA and plasmids were purchased from Promega,
TopoGEN or invitrogen.
In vitro enzymatic assays
DNA topoisomerase VI assays. The enzyme activities were
carried out in a ﬁnal volume of 20 ml containing 35 mM
HEPES (pH 7.5), 40 mM KCl, 10 mM MgCl2, 0.5 mM
ATP, 2 mM DTT, 1 mM spermidine, 0.1 mM EDTA and
either 0.2 mg of kDNA (for decatenation assays) or 0.2 mg
of pBR322 plasmids (for relaxation and supercoiling assays).
Reactions were incubated with 2 U of enzyme for 4 or 6 min at
74 C (1 U of enzyme being deﬁned as the amount of enzyme
required to completely decatenate 0.2 mg of kDNA in 6 min at
74 C or relaxed 0.2 mg of pBR322 in 4 min at 74 C) and with
various concentrations of drugs dissolved in DMSO (or H2O
for novobiocin), ranging from 25 to 1000 mM. The reactions
were terminated by cooling to 0 C, and immediately after
the addition of 0.1 volume of loading dye (50% glycerol
and 0.025% bromophenol blue). Samples were loaded and
run at 35 mV (for relaxation assays) or 50 mV (for decatena-
tion assays) directly onto a 1% agarose gel with or without
ethidium bromide (EtBr). Gels were stained with 0.5 mg/ml of
EtBr for 20 min and photographed. The stability of the drugs at
the DNA topoisomerase VI incubation temperature (74 C)
were tested by preincubation of these drugs during 2–30 min.
The kDNA assay was done using a catenated DNA substrate
prepared from the kinetoplast of the insect trypanosome
Crithidia fasciculata. kDNA is an aggregate of interlocked
DNA minicircles (mostly 2.5 kb) that form extremely large
networks of high molecular weight. As a result, these networks
fail to enter an agarose gel. Upon incubation with a type II
DNA topoisomerase, which engages DNA in a double-
stranded breaking and reunion cycle, minicircular DNAs
are released (decatenated). The decatenated minicircles
move rapidly into the gel owing to their small size.
DNA gyrase assays. Assays with DNA gyrase were carried out
at 37 C in the same way as DNA topoisomerase VI, but with
its speciﬁc buffer and for 30 min (see TopoGEN protocols:
http://www.topogen.com).
In vivo drugs treatments
S.acidocaldarius (strain DSM639), H.volcanii (strain DS2)
and E.coli K12 C600 were grown in liquid shaken cultures
(200 r.p.m.) at 78, 45 and 37 C, respectively. The growth
media were as described by Lopez-Garcia and Forterre (17)
for S.acidocaldarius, by Allers et al. (18) for H.volcanii
Nucleic Acids Research, 2005, Vol. 33, No. 7 2311(medium AHv-YPC). LB classical medium was used for
E.coli. To test the effect of drugs on cell growth, stationary
phase cultures were dilutedinto fresh medium and grown up to
an optical density in the range of 0.05–0.2 OD. The cultures
were then divided into several samples and supplemented with
drugsatvarious concentrations.Thegrowthofthe threestrains
was insensitive to DMSO at the concentrations used.
The different cultures were cultivated up to 24 h in the
presence of drugs and regularly sampled for absorbance mon-
itoring (at 600 nm) and microscopic examination (with a
Nikon eclipse E600 microscope ·100). Control cultures with-
outdrugs were growninparallel under thesameconditions.To
test the reversibility of the drug effects, some 24 h cultures
were centrifuged at 10000 r.p.m. in a Sorvall centrifuge, the
pellets were washed with fresh media, resuspended in the
initial volume of growth medium, and grown for an additional
24 h. To test the stability of the radicicol at the condition
employed for Sulfolobus growth, ﬁve ﬂasks with 10 ml of
Sulfolobus culture medium were incubated at 74 C, one for
control without drug, and the four others with 100 mMo f
radicicol. The Sulfolobus cells (1 ml at optical density of
0.62) were added at time 0, 2, 4 or 6 h after radicicol. The
absorbance of the different cultures after the inoculation was
checked every 2 h for growth curves.
RESULTS
In vitro assays
We ﬁrst tested the effect of various concentrations of radicicol
and geldanamycin on the decatenation activity of S.shibatae
DNA topoisomerase VI. As shown in Figure 1a, DNA
topoisomerase VI was strongly inhibited by radicicol in a
dose-dependent manner. Some inhibition was visible above
50–100 mM of drug and nearly complete inhibition was
observed at radicicol concentrations of 200 mM. In contrast,
geldanamycin was inactive in the decatenation assay at con-
centrations up to 250 mM (Figure 1b). Radicicol also inhibited
strongly relaxation by S.shibatae DNA topoisomerase VI in a
dose-dependent manner and in the same range of concentra-
tions. As shown in Figure 2, inhibition of relaxation was
already clearly visible at 50–100 mM and complete at 125 mM.
To be sure that radicicol did not induce the cleavable complex,
we have also performed the classical experiment usedtoreveal
such complex (addition of SDS and proteinase K before elec-
trophoresis). No linear form appeared after such treatment
(data not shown). As fordecatenation, relaxation by S.shibatae
DNA topoisomerase VI was not sensitive to geldanamycin
(data not shown).
Both Topo IIA and Topo IIB bear a Bergerat fold, so radi-
cicol could have been a general inhibitor of type II DNA
topoisomerases. To check this possibility, we tested the effect
of radicicol on the supercoiling activity of E.coli DNA gyrase
(a Topo IIA). As shown in Figure 3, supercoiling of E.coli
DNA gyrase was not inhibited by radicicol (up to 500 mM),
indicating that radicicol exhibits speciﬁcity towards different
type II DNA topoisomerases. Novobiocin was used as a
positive control against gyrase activity.
Figure 3. Agarose gel electrophoresis showing the effect of radicicol on
supercoiling of the plasmid pBR322 by the DNA gyrase. Lane 1, control
pBR322 negatively supercoiled; lane 2, relaxed pBR322 and 500 mM
radicicol without gyrase; lane 3, relaxed pBR322 with gyrase; lanes 4 and
5, relaxed pBR322 with gyrase in the presence of 100 or 500 mM radicicol;
andlane6,relaxedpBR322withgyraseinthe presenceof100mMnovobiocin.
Figure 1. Agarose gel electrophoresis showing the effect of radicicol (a) and
geldanamycin (b) on decatenation of kDNA by the DNA topoisomerase VI.
Lane 1, linear kDNA marker (L); lane 2, decatenated kDNA marker: nicked,
open circular (N) and relaxed DNA (R); lane 3, catenated kDNA (C); lane 4,
kDNA with Topo VI; lane 5, kDNA with TopoVI and DMSO;and lanes 6–11,
kDNA with Topo VI in the presence of radicicol or geldanamycin (250, 200,
125, 100, 50 and 25 mM, respectively).
Figure 2. Agarose gel electrophoresis showing the effect of radicicol on
relaxation of the plasmid pBR322. Lane 1, supercoiled pBR322; lane 2,
supercoiled pBR322 in the presence of radicicol (250 mM); lane 3,
supercoiled pBR322 with Topo VI; lane 4, supercoiled pBR322 with Topo
VI and DMSO; and lanes 5–10, supercoiled pBR322 with Topo VI in the
presence of radicicol (25, 50, 100, 125, 200 and 250 mM, respectively). SC:
negatively supercoiled pBR322 DNA; R: relaxed DNA; OC: open circular
(nicked) pBR322 DNA.
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We have tested the effect of radicicol and geldanamycin
in vivo on the growth of two archaea harbouring a DNA
topoisomerase VI, the crenarchaeon S.acidocaldarius (an
extreme thermophile and acidophile) and the euryarchaeon
H.volcanii (an extreme halophile). As illustrated in Figure 4,
both Archaea were sensitive to radicicol in the same concen-
tration range than Sulfolobus DNA topoisomerase VI in vitro.
The MIC for radicicol in vivo with Haloferax was below
12 mg/ml, and was between 36 and 73 with Sulfolobus.
In agreement with in vitro data, the growth of both S.acidocal-
darius and H.volcanii were in contrast fully resistant to
geldanamycin (data not shown).
As shown in Figure 4, Sulfolobus growth resumed after 10 h
of exposure to radicicol, suggesting that this drug was unstable
at high temperature in the acidic medium used to cultivate
Sulfolobus. Figure 5 shows that preincubation of this drug in
the culture medium for >6 h completely suppressed the radi-
cicol inhibition. In another experiment (data not shown),
addition of a second radicicol dose (after centrifugation and
resuspension of the culture), 2 or 4 h after the ﬁrst one pro-
duced a complete arrest of Sulfolobus growth.
In contrast, Haloferax growth only resumed after 25 h of
exposure, indicating that this drug was more stable in the
medium and culture conditions used to cultivate halophilic
archaea.
Figure 4. In vivo inhibition of radicicol on Haloferax and Sulfolobus growths. Effect of different drug concentrations of radicicol measured by monitoring the
cultures’ absorbances at 600 nm.
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by the addition of radicicol (data not shown) whereas
Haloferax cells morphology (Figure 6a) was drastically
altered, with the appearance of large rod-shaped cells
(Figure 6b). The effect of radicicol on H.volcanii was revers-
ible, since growth resumed (Figure 6d) and cells regained their
initial morphology after drug removal (Figure 6c).
In order to identify possible alternative in vivo targets of
radicicol in S.acidocaldarius and H.volcanii, we looked for all
Bf proteins present in H.volcanii, Sulfolobus solfataricus and
Sulfolobus tokodai by screening the complete set of proteins
encoded by their genomes for conserved amino acid signatures
speciﬁc for the Bergerat fold (data not shown). DNA topo-
isomerase VI turned out to be the only Bf protein that we could
detect in the genomes of the two Sulfolobus, strengthening the
idea that this enzyme is the intracellular target of radicicol
in vivo in S.acidocaldarius. In contrast, we could detect 16 Bf
proteins encoded by the H.volcanii genome, including DNA
topoisomerase VI, DNA gyrase, 13 histidine kinases and a
MutL homologue. As a control, we thus tested the effect of
radicicol on the growth of E.coli which similarly encodes
MutL and up to 29 histidines kinases (Table 1) but only con-
tain members of the Topo IIA family. As shown in Figure 7,
E.coli was not sensitive to radicicol and geldanamycin, but
fully inhibited by two speciﬁc Topo IIA inhibitors, novobiocin
and ciproﬂoxacin.
Modelization of radicicol–DNA topoisomerase VI
complex
Both radicicol and geldanamycin inhibit Hsp90 by interact-
ing with its Bergerat fold (16). Our data suggested that only
radicicol could interact with the Bergerat fold of DNA topo-
isomerase VI or that interaction with geldanamycin did not
produce inhibition. To get insight into this question, we have
modelled the putative interactions of these two drugs and
ATP with DNA topoisomerase VI, Hsp90 and the histidine
kinase using coordinates obtained from the crystal structure
of the B subunit of S.shibatae DNA topoisomerase VI [(9),
PDB code:1MX0], the Saccharomyces cerevisiae Hsp90
radicicol complex [(16), PDB code: 1BGQ], and the Ther-
motoga maritima histidine kinase CheA [(19), PDB code:
1I59]. The superimposition of these structures (root mean
square deviation of 1.5 s) shows that radicicol can be ﬁtted
in the ATP-binding pocket of DNA topoisomerase VI with-
out steric clashes. On the contrary, a similar model built
from the structure of the geldanamycin-Hsp90 ATP-binding
domain [(19), PDB code 1a4h], shows that geldanamycin is
too large to be accommodated without drastic confor-
mational changes in the ATP-binding pocket of DNA
(a) (b)
(c)
(d)
Figure 6. Effect of radicicol treatment (60 mM) on the morphology of
H.volcanii. Microscopic observations ·100. (a) Cells before radicicol
addition; (b) cells at time 24 h after radicicol addition (the culture has been
concentrated by centrifugation for microscopic observation); (c) cells at time
24 h after removal of radicicol and resuspension; and (d) growth curves
before and after removal of radicicol.
Figure 5. Stability of radicicol at 74 C in the Sulfolobus medium. Five flasks
with 10 ml of Sulfolobus culture medium were incubated at 74 C, one for
control without drug (flask T), and the four others with 100 mM of radicicol
(flasksR:0,R:2,R:4andR:6).Attime=0h,1mlofaSulfolobusculture(ODof
0.62) was added to flasks T and R:0, at time = 2, 4 and 6 h, 1 ml of the same
Sulfolobusculture(OD of0.62) wasadded, respectively, to flasks R:2, 4 and 6.
Table 1. Potential targets of radicicol (containing the ATPase domain of
HSP90 chaperone/DNA topoisomerase II/histidine kinase: http://supfam.
mrc-lmb.cam.ac.uk/SUPERFAMILY/index.html)
Halobacteria Sulfolobales E.coli Eukaryotes
Gyrase/Topo IV ++ (2) + (plants)
Topo II +
Topo VI ++ + (plants)
Histidines kinases +(13) +(29) +
Hsp90 family ++
MutL family ++ +
2314 Nucleic Acids Research, 2005, Vol. 33, No. 7topoisomerase VI (Figure 8). As controls, we compare our
models with the Hsp90-radicicol and geldanamycin com-
plexes and model their interaction with the histidine kinase
CheA (Figure 8). As previously shown (16), both radicicol
and geldanamycin ﬁt perfectly in the ATP-binding site of
Hsp90. In contrast, radicicol could not ﬁt in the ATP-binding
site of CheA. The latter observation could explain why the
presence of histidine kinase does not seem to be correlated
to the sensitivity to radicicol. These in silico data could
nicely explain the differences observed between the effects
of radicicol and geldanamycin on archaeal DNA topoi-
somerase VI.
DISCUSSION
Radicicol was isolated 50 years ago from the fungus
Monospirium bonorden (20) and was ﬁrst described as a tyr-
osine kinase inhibitor. Later on, it was shown to inhibit signal
transduction of oncogene products and to exhibit potent
Figure 8. SlicedsurfacerepresentationoftheS.shibataeDNAtopoisomerase VI,S.cerivisiaeHsp90andT.maritimahistidinekinaseATP-binding sitescomplexed
with ATP, radicicol and geldanamycin. The ligands are shown in sticks. Opaque regions correspond to the interior of the enzymes molecules.
Figure 7. Effect of different drugs on E.coli growth measured by monitoring
the cultures’ absorbances at 600 nm.
Nucleic Acids Research, 2005, Vol. 33, No. 7 2315in vitro antiproliferative activity against a wide variety of
tumour cell lines (21). Finally, the actual intracellular target
of radicicol in mammalian cells turned out to be the Hsp90
protein (16,22). Hsp90, which is one of the most abundant
chaperones in eukaryotes, participates in folding and stabil-
ization of signal-transducing molecules, including steroid
hormone receptors and protein kinases. Radicicol induces
destabilization of Hsp90-dependent client proteins by binding
with high afﬁnities to the N-terminal domain of the
chaperone (16,22,23). This binding prevents the correct
maturation of the client proteins, leading to their degradation
by the proteasome.
The three-dimensional structure of the complex between
radicicol and Hsp90 has shown that the drug speciﬁcally
binds to the ATP-binding site of Hsp90 (24). This site corres-
ponds to a recently described ATP-binding module known as
the Bergerat fold (8). This fold is also present in the B subunits
of type II DNA topoisomerases (both Topo IIA and Topo IIB),
in the mismatch repair protein MutL and in various histidine
and serine kinases (2,8,25,26). The speciﬁc binding of radi-
cicol and geldanamycin to the Hsp90 Bergerat fold suggested
that other proteins with a Bergerat fold (Bf proteins) could be
sensitive to these drugs. This turned out to be the case for
branched-chain alpha-keto acid dehydrogenase kinase (BCK-
DHK) and Sln1 yeast histidine kinase (27).
Here, we have shown that radicicol inhibits in vitro the
activity of another Bf protein, S.shibatae DNA topoisomerase
VI (the prototype of the Topo IIB family). In contrast, radi-
cicol has no effect on a Bf protein representative of the Topo
IIA family, E.coli DNA gyrase. The resistance of bacterial
DNA gyrase to radicicol indicate that this drug can target
speciﬁcally some families of Bf proteins, since bacterial
Topo IIA (both DNA gyrase and Topo IV) also bear a Bergerat
fold. This is reminiscent of data previously obtained with
another Bf interacting drug, novobiocin (28,29), since this
classical inhibitor of Topo IIA has no effect on S.shibatae
DNA topoisomerase VI (15).
In agreement with our in vitro observations, we found that
radicicol inhibits the growth of two archaea that contain DNA
topoisomerase VI, S.acidocaldarius and H.volcanii but has no
effect on E.coli that only contains Topo IIA (DNA gyrase and
DNA topoisomerase IV). Although the deﬁnitive proof will
require genetic experiments, the good correlation between
our in vitro and in vivo data strongly suggests that archaeal
DNA topoisomerase VI are the targets of radicicol in vivo.I n
agreementwiththisconclusion,theinhibitionofH.volcaniiand
S.acidocaldarius by radicicol in vivo occurs at doses that are in
the concentration range of those effective on S.shibatae Topo
VI in vitro. Furthermore, DNA topoisomerase VI is the
onlyBfproteinthatcanbedetectedinthegenomeofSulfolobus.
In the case of H.volcanii, one cannot formally exclude that
radicicol inhibits in vivo other Bf proteins encoded by the
genomeofthis archaeon (eitherMutL and/orhistidinekinases)
butourmodelization predictionwith thehistidinekinaseCheA
suggests that this enzyme should not be inhibited by radicicol,
strengthens our point that Topo VI is also probably the target
of radicicol in Haloferax.
The inhibition of both S.acidocaldarius and H.volcanii by
radicicol suggests that this drug is a general inhibitor for
archaeal DNA topoisomerase VI and possibly for their homo-
logues in plants.
In contrast to radicicol, the drug geldanamycin, another
Hsp90 inhibitor that also interacts with the Bergerat fold,
has no effect on the activity of S.shibatae DNA topoisomerase
VI in vitro and did not inhibit the growth of the two archaea
tested. This result ﬁts well with modelling experiments show-
ing that radicicol can be located in the ATP-binding pocket
located in the Bergerat fold of DNA topoisomerase VI,
whereas geldanamycin cannot (Figure 8). This favours the
idea that, as in the case of Hsp90, radicicol inhibits DNA
topoisomerase VI by interacting with the Bergerat fold of
its B subunit.
If we assume that the in vivo target of radicicol in
S.acidocaldarius and H.volcanii is DNA topoisomerase VI,
our in vivo results point to an essential role for this enzyme
in these two archaea. This is not surprising in the case of
S.acidocaldarius, since DNA topoisomerase VI is the only
type II DNA topoisomerase present in the two Sulfolobus
whose genomes have been completely sequenced. Further-
more, the three other DNA topoisomerases (type I) present
in Sulfolobus species (two reverse gyrases and a relaxing
enzyme) belong to a superfamily (Topo IA) whose members
cannot relax positive supercoils and cannot decatenate intact
DNA duplexes. Accordingly, DNA topoisomerase VI should
be essential in Sulfolobus both for the decatenation of daugh-
ter chromosomes at the end of one DNA replication round,
and to remove positive supercoils that would otherwise accu-
mulate in front of DNA replication forks and transcribing
RNA polymerases.
In the case of H.volcanii, the inhibition by radicicol was not
predictable, since this archaeon also contains a DNA gyrase
that could theoretically replace the missing activities of DNA
topoisomerase VI in radicicol-treated cells. It was already
known that DNA gyrase is essential for halophilic archaea,
since their growth is inhibited by novobiocin (30,31). The
inhibition of Haloarchaea by radicicol reported here thus
indicates that both DNA gyrase and DNA topoisomerase VI
are essential in these archaea. These two enzymes have pos-
sibly specialized roles, as in the case of DNA gyrase and DNA
topoisomerase IV in bacteria. DNA gyrase is probably essen-
tial in Haloarchaea because some critical steps in DNA func-
tion, such as initiation of DNA replication and/or transcription
at some promoters, are dependent on negative supercoiling.
Indeed, negatively supercoiled plasmid of Halobacterium
GRB became positively supercoiled after novobiocin treat-
ment in vivo (31). It is not so clear why DNA topoisomerase
VI is essential in H.volcanii. One possibility is that DNA
topoisomerase VI speciﬁcally interacts with other proteins
for proper chromosome segregation and cell division. This
would be reminiscent of the speciﬁc interaction of DNA
topoisomerase IV with the cell division protein FtsK in
E.coli (32). A strong involvement of DNA topoisomerase
VI in cell division would explain why addition of radicicol
to cultures of H.volcanii triggers cell ﬁlamentation (Figure 6).
We anticipate that radicicol will be a very useful tool to
further study the mechanism of action of DNA topoisomerase
VI in vitro, and to analyse its role in vivo in archaea. An
appealing property of radicicol is its ability to discriminate
between Topo IIA and Topo IIB. The discovery of a new
archaeal inhibitor should also help for the development of
the genetic tools in archaea by providing the possibility
to design selectable markers based on the top6B gene.
2316 Nucleic Acids Research, 2005, Vol. 33, No. 7The discovery that radicicol inhibits DNA topoisomerase VI
can also have implication for studies in eukaryotic systems.
For instance, DNA topoisomerase VI appears to be essential
for endo-reduplication in plant, a process that triggers cell
polyploidy and controls cellular and plant size (33,34). It
has already been shown that addition of radicicol has a pro-
found effect on plant morphology and this effect has been
attributed to Hsp90 (33). However, some of the observed
effects could have been also mediated via DNA topoisomerase
VI inhibition. Finally, our experimental observations com-
bined with modelization conﬁrm that distinct families of Bf
proteinscanbesensitivetoradicicol while someotherscannot.
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